var data={"title":"Activated charcoal: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Activated charcoal: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5864?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=activated-charcoal-drug-information\" class=\"drug drug_general\">see &quot;Activated charcoal: Drug information&quot;</a> and <a href=\"topic.htm?path=activated-charcoal-patient-drug-information\" class=\"drug drug_patient\">see &quot;Activated charcoal: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149199\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Actidose-Aqua [OTC];</li>\n      <li>Actidose/Sorbitol [OTC];</li>\n      <li>Char-Flo with Sorbitol [OTC];</li>\n      <li>EZ Char [OTC];</li>\n      <li>Kerr Insta-Char in Sorbitol [OTC];</li>\n      <li>Kerr Insta-Char [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149200\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Charac-25 [OTC];</li>\n      <li>Charac-50 [OTC];</li>\n      <li>Charactol-25 [OTC];</li>\n      <li>Charactol-50 [OTC];</li>\n      <li>Charcodote Susp [OTC];</li>\n      <li>Charcodote TFS [OTC];</li>\n      <li>Charcodote-Aqueous Sus;</li>\n      <li>Premium Activated Charcoal [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051616\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidiarrheal</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Adsorbent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiflatulent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051609\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=activated-charcoal-drug-information\" class=\"drug drug_general\">see &quot;Activated charcoal: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric: <b>Acute poisoning:</b> Oral, NG:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Single dose: Charcoal <b>in water</b>: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Age-directed dosing: <b>Note:</b> Although dosing by body weight in children (0.5 to 1 g/kg) is recommended by several resources, there are no data or scientific rationale to support this recommendation (Chyka 2005). </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants &lt;1 year: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Manufacturer's labeling (Actidose-Aqua): 1 g/kg </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">AACT recommendation (Chyka 2005): 10 to 25 g</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 1 to 12 years: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\"> Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Actidose-Aqua: 25 to 50 g</p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Kerr Insta-Char (Aqueous): Weight &ge;16 kg: 1 to 2 g/kg <b>or</b> 15 to 30 g </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">AACT recommendation (Chyka 2005): 25 to 50g</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Actidose-Aqua: 50 to 100 g </p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Kerr Insta-Char (Aqueous): Weight &ge; 32kg: 1 to 2 g/kg <b>or</b> 50 to 100 g </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">AACT recommendation (Chyka 2005): 25 to 100 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Single dose: Charcoal <b>with sorbitol</b>; </i>  <b>Note:</b> Use of oral charcoal with sorbitol as part of a multiple dose activated charcoal regimen is not recommended (AACT [Vale 1999]); however, a single dose may be used to produce catharsis (AACT 2004): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants &lt;1 year: Not recommended </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to 12 years (Actidose with Sorbitol):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Weight 16 to &lt;32 kg: 25 g</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Weight &ge; 32 kg: 25 to 50 g</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Actidose with Sorbitol: 50 g</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Kerr Insta-Char in Sorbitol: Weight &ge;32 kg: 1 to 2 g/kg <b>or</b> 50 to 100 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Multiple dose: Charcoal <b>in water</b></i> (doses are repeated until clinical observations of toxicity subside and serum drug concentrations have returned to a subtherapeutic range or until the development of absent bowel sounds or ileus); <b>Note:</b> Reserve for life threatening ingestions of carbamazepine, dapsone, phenobarbital, quinine, or theophylline (AACT 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Manufacturer's labeling (Actidose-Aqua):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants &lt;1 year: 1 g/kg every 4 to 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 1 to 12 years: 25 to 50 g every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents: 50 to 100 g every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: <b>Acute poisoning:</b> Oral, NG: <b>Note:</b> Some products may contain sorbitol; coadministration of a cathartic, including sorbitol, is not recommended. Some clinicians still recommend dosing activated charcoal in a 10:1 (charcoal:poison) ratio for optimal efficacy (Gude 2009); however, the amount of poison ingested is commonly unknown, which makes this approach challenging and often impractical (Chyka 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Single dose (Chyka 2005): 25 to 100 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Multidose: Initial dose: 50 to 100 g followed by 25 to 50 g every 4 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149185\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Actidose-Aqua: 15 g/72 mL (72 mL); 25 g/120 mL (120 mL); 50 g/240 mL (240 mL) [sweet flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Actidose/Sorbitol: 25 g/120 mL (120 mL); 50 g/240 mL (240 mL) [sweet flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kerr Insta-Char: 25 g/120 mL (120 mL); 50 g/240 mL (240 mL) [contains fd&amp;c red #40, methylparaben sodium, propylene glycol, propylparaben sodium, sodium benzoate; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kerr Insta-Char: 50 g/240 mL (240 mL) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kerr Insta-Char in Sorbitol: 25 g/120 mL (120 mL); 50 g/240 mL (240 mL) [contains fd&amp;c red #40, methylparaben sodium, propylene glycol, propylparaben sodium, sodium benzoate; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Char-Flo with Sorbitol: 25 g (120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EZ Char: 25 g (1 ea) [contains bentonite]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149172\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051619\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer as soon as possible after ingestion, preferably within 1 hour for greatest effect. Shake well before use; may be mixed with chocolate syrup or orange juice to increase palatability. Manufacturer's labeling for Actidose Aqua and Actidose with sorbitol recommends avoiding adding chemicals, syrups, or dairy products. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Instruct patient to drink slowly, rapid administration may increase frequency of vomiting; if patient has persistent vomiting, multiple doses may be administered as a continuous enteral infusion </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149194\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Adsorbs gases from air, store in a closed container.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051618\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Emergency treatment in poisoning by drugs and chemicals (FDA approved in all ages); repetitive doses for GI dialysis in drug overdose to enhance the elimination of certain drugs (theophylline, phenobarbital, carbamazepine, dapsone, quinine) (FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149220\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Actidose may be confused with Actos</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149219\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distention, appendicitis, constipation, dental discoloration (black; temporary), fecal discoloration (black), intestinal obstruction, mouth discoloration (black; temporary), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Corneal abrasion (with direct contact)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Aspiration, respiratory failure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149190\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no absolute contraindications listed within the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> The American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) consider the following to be contraindications to the use of charcoal  (Chyka 2005; Vale 1999): Presence of intestinal obstruction or GI tract not anatomically intact; patients at risk of GI hemorrhage or perforation; patients with an unprotected airway (eg, CNS depression without intubation); if use would increase the risk and severity of aspiration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149176\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vomiting: Charcoal may cause vomiting; the risk appears to be greater when charcoal is administered with sorbitol (Chyka 2005). IV antiemetics may be required to reduce the risk of vomiting or to control vomiting to facilitate administration (Vale 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Decreased peristalsis: Use with caution in patients with decreased peristalsis. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ipecac: Ipecac should not be administered routinely in the management of poisoned patients (AACT 2004b). In addition, use may delay the administration of or decrease the effectiveness of activated charcoal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cathartics (eg, sorbitol, mannitol, magnesium sulfate): Coadministration of a cathartic is <b>not</b> recommended; cathartics have not been demonstrated to change patient outcome and have no role in the management of the poisoned patient. Cathartics subject the patient to the risk of developing significant fluid and electrolyte abnormalities (AACT 2004a).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Capsules: Not recommended for use in the treatment of poisoning.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP [&quot;Inactive&quot; 1997]; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sorbitol: Some products may contain sorbitol; coadministration of a cathartic, including sorbitol, is <b>not</b> recommended. Do not use products containing sorbitol in patients with a genetic intolerance to fructose or in patients who are dehydrated; may cause excessive diarrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tablets: Not recommended for use in the treatment of poisoning.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Not effective in the treatment of poisonings due to the ingestion of low molecular weight compounds such as cyanide, iron, ethanol, methanol, or lithium. Avoid use in hydrocarbon and caustic ingestions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Efficacy: Most effective when administered within 30-60 minutes of ingestion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Multidose administration: Based on experimental and clinical studies, multidose activated charcoal, in most acute poisonings, has not been shown to reduce morbidity or mortality (Vale 1999). It may be considered if a patient has ingested a life-threatening amount of carbamazepine, dapsone, phenobarbital, phenytoin, quinine, or theophylline, although no controlled studies have demonstrated clinical benefit.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855388\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Excessive amounts of activated charcoal with sorbitol may cause hypernatremic dehydration in pediatric patients (Farley 1986); use  is not recommended in infants &lt;1 year of age. Aspiration may cause tracheal obstruction in infants but usually not a major problem in adults. Aspiration pneumonitis, bronchiolitis obliterans, and ARDS have been reported following aspiration of charcoal; however, these problems may be due to the aspiration of gastric contents and not charcoal per se. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some products contain fructose or sorbitol and should not be administered to patients with a rare autosomal recessive genetic intolerance to fructose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299010\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149180\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13142&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Charcoal, Activated may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to charcoal when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: Charcoal, Activated may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to charcoal when possible. Separating drug administration is not likely to be effective at avoiding this interaction.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149196\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">The addition of some flavoring agents (eg, milk, ice cream, sherbet, marmalade) are known to reduce the adsorptive capacity, and therefore the efficacy, of activated charcoal and should be avoided in preference to activated charcoal-water slurries; nevertheless, these flavoring agents do not completely compromise the effectiveness of activated charcoal and may be necessary in some circumstances (eg, administration in pediatric patients) to enhance compliance (Cooney 1995; Dagnone 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13657798\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Activated charcoal is not absorbed systemically following oral administration. Use during pregnancy is not expected to result in significant exposure to the fetus. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051615\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Check for presence of bowel sounds before administration. Fluid status, sorbitol intake, number of stools, electrolytes if increase in stools or diarrhea occurs; continually assess for active bowel sounds in patients receiving multiple dose activated charcoal</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149175\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Adsorbs toxic substances, thus inhibiting GI absorption and preventing systemic toxicity.  Administration of multiple doses of charcoal may interrupt enteroenteric, enterohepatic, and enterogastric circulation of some drugs; may also adsorb any unabsorbed drug which remains in the gut.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149189\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In studies using adult human volunteers: Mean <b>reduction</b> in drug absorption following a single dose of &ge;50 g activated charcoal (AACT [Chyka 2005]): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Given within 30 minutes after ingestion: 47.3% reduction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Given at 60 minutes after ingestion: 40.07% reduction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Given at 120 minutes after ingestion: 16.5% reduction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Given at 180 minutes after ingestion: 21.13% reduction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Given at 240 minutes after ingestion: 32.5% reduction </p>\n    <p style=\"text-indent:0em;\">Absorption: Not absorbed from the GI tract </p>\n    <p style=\"text-indent:0em;\">Excretion: Feces (as charcoal)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051624\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">The Position Paper on single dose activated charcoal by The American Academy of Clinical Toxicology and The European Association of Poisons Centres and Clinical Toxicologists (Chyka 2005) does not advocate <b>routine</b> use of single dose activated charcoal in the treatment of poisoned patients. Scientific literature supports the use of activated charcoal within 1 hour of toxin ingestion, when it will be more likely to produce benefit. Studies in volunteers demonstrate that the effectiveness of activated charcoal decreases as the time of administration after toxin ingestion increases. Therefore, this publication states that activated charcoal may be considered up to 1 hour following ingestion of a potentially toxic amount of poison. In addition, the use of activated charcoal may be considered greater than 1 hour following ingestion, since the potential benefit cannot be excluded. Furthermore, based on current literature, the routine administration of a cathartic with activated charcoal is not recommended; when cathartics are used, only a single dose should be administered so as to decrease adverse effects (AACT 2004). </p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">A policy statement by the American Academy of Pediatrics states that it is currently premature to recommend the <b>routine</b> administration of activated charcoal as a home treatment strategy for poisonings (AAP 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323056\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Kerr Insta-Char in Sorbitol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 g/120 mL (120 mL): $29.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 g/240 ml (240 mL): $40.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Kerr Insta-Char Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 g/120 mL (120 mL): $29.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 g/240 ml (240 mL): $40.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Char-Flo with Sorbitol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25-48 g/120 mL (120 mL): $6.12</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149192\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acticarb (AE, EG);</li>\n      <li>Antipois (VN);</li>\n      <li>Bekarbon (ID);</li>\n      <li>Biocarbon (AT, MT, MY);</li>\n      <li>Ca-R-Bon (TH);</li>\n      <li>Carbo Medicinalis (PL);</li>\n      <li>Carbomint (VN);</li>\n      <li>Carbomix (DK, FR, MT, SE, TR, TW);</li>\n      <li>Carbon Natural (UY);</li>\n      <li>Carbosorb (CZ, NZ);</li>\n      <li>Carbosorb X (AU, NZ);</li>\n      <li>Carbosorb XS (AU, NZ);</li>\n      <li>Carbotox (SK);</li>\n      <li>Carbotural (MX);</li>\n      <li>Charcodote (GB, KR, SG);</li>\n      <li>Charcotrace (AU, KR);</li>\n      <li>Deltacarbon (TH);</li>\n      <li>Eucarbon (QA);</li>\n      <li>JL Bragg's Medicinal Charcoal (HK);</li>\n      <li>Karbosorb (HU);</li>\n      <li>Koal (BD);</li>\n      <li>Kremezin (TW);</li>\n      <li>Mamograf (AR);</li>\n      <li>Neocarbon (BR);</li>\n      <li>Norit (IL);</li>\n      <li>RCOL (IN);</li>\n      <li>Ultra Carbon (AE, CY, EG);</li>\n      <li>Ultracarbon (MY, SG, TR);</li>\n      <li>Yo'Come Penney (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Actidose suspension (charcoal, activated) [prescribing information]. Minneapolis, MN: Paddock Laboratories, Inc; June 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), &quot;Position Paper: Cathartics,&quot; <i>J Toxicol Clin Toxicol</i>, 2004, 42(3):243-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-pediatric-drug-information/abstract-text/15362590/pubmed\" target=\"_blank\" id=\"15362590\">15362590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention, &ldquo;Poison Treatment in the Home,&rdquo; <i>Pediatrics</i>, 2003, 112(5):1182-5. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-pediatric-drug-information/abstract-text/ 14595067 /pubmed\" target=\"_blank\" id=\" 14595067 \"> 14595067 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a>http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chyka PA, Seger D, Krenzelok EP, et al, &quot;Position Paper: Single-Dose Activated Charcoal,&quot; <i>Clin Toxicol (Phila)</i>, 2005, 43(2):61-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-pediatric-drug-information/abstract-text/15822758/pubmed\" target=\"_blank\" id=\"15822758\">15822758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooney DO, <i>Development of Palatable Formulations, Activated Charcoal in Medical Applications</i>, Cooney DO, ed, New York, NY: Marcel Dekker, Inc, 1995, 397-417.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dagnone D, Matsui D, and Rieder MJ, &quot;Assessment of the Palatability of Vehicles for Activated Charcoal in Pediatric Volunteers,&quot; <i>Pediatr Emerg Care</i>, 2002, 18(1):19-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-pediatric-drug-information/abstract-text/11862132/pubmed\" target=\"_blank\" id=\"11862132\">11862132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farley TA, &ldquo;Severe Hypernatremic Dehydration After Use of an Activated Charcoal-Sorbitol Suspension,&rdquo; <i>J Pediatr</i>, 1986, 109(4):719-22. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-pediatric-drug-information/abstract-text/3761093 /pubmed\" target=\"_blank\" id=\"3761093 \">3761093 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gude AB, Hoegberg LC, Angelo HR, Christensen HR. Dose-dependent adsorptive capacity of activated charcoal for gastrointestinal decontamination of a simulated paracetamol overdose in human volunteers. <i>Basic Clin Pharmacol Toxicol</i>. 2010;106(5):406-410. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-pediatric-drug-information/abstract-text/20002061 /pubmed\" target=\"_blank\" id=\"20002061 \">20002061 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kerr Insta-Char (charcoal, activated) [prescribing information]. Birmingham, AL: Vista-Pharm, Inc; January 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kerr Insta-Char in sorbitol base (charcoal, activated) [prescribing information]. Birmingham, AL: Vista-Pharm, Inc; June 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vale JA, Krenzelok EP and Barceloux GD et al, American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists, &ldquo;Position Statement and Practice Guidelines on the Use of Multiple-Dose Activated Charcoal in the Treatment of Acute Poisoning,&rdquo; <i>Clin Toxicol</i>, 1999, 37(6):731-51.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13142 Version 97.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F149199\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F149200\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051616\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051609\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F149185\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F149172\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051619\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F149194\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051618\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F149220\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F149219\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F149190\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F149176\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855388\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299010\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F149180\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F149196\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13657798\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1051615\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F149175\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F149189\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1051624\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323056\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F149192\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13142|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=activated-charcoal-drug-information\" class=\"drug drug_general\">Activated charcoal: Drug information</a></li><li><a href=\"topic.htm?path=activated-charcoal-patient-drug-information\" class=\"drug drug_patient\">Activated charcoal: Patient drug information</a></li></ul></div></div>","javascript":null}